Back
Repligen Corp (RGEN)
Life Sciences Tools & ServicesRGEN · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$173.88
+6.13%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$0.86
ROE
2.5%
Gross margin
53.1%
Debt/Equity
0.33x
Revenue growth
14.8%
Repligen Corp — company intelligence
Earnings surprises
Q2 2026$0.54 vs $0.46 est+18.0%
Q1 2026$0.48 vs $0.39 est+21.9%
Q4 2025$0.49 vs $0.45 est+9.3%
Q3 2025$0.46 vs $0.43 est+7.8%
Analyst consensus · 28 analysts
24 Buy4 Hold0 Sell
Updated Oct 10, 2026
Insider activity · 90 days
2 buys7 sellsnet -8,311 shares
Douglass Brian RobbBuy 675 · Oct 6, 2026
Douglass Brian RobbBuy 700 · Oct 6, 2026
Loeillot Olivierother 4,202 · Oct 5, 2026
Recent SEC filings
4 — Insider transaction reportOct 8, 2026
4 — Insider transaction reportOct 6, 2026
8-K — Material event reportOct 6, 2026
Latest news
Barclays Maintains Overweight on Repligen, Raises Price Target to $225 — Benzinga · 3d ago
Why Are Freshworks (FRSH) Shares Soaring Today — Yahoo · 4d ago
Repligen Completes Acquisition of BioLife Solutions — Yahoo · 4d ago
Freshworks Set to Join S&P SmallCap 600 — Yahoo · 5d ago
Freshworks stock climbs on S&P SmallCap 600 inclusion — Yahoo · 5d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.